article thumbnail

Introducing the Borderline Personality Disorder Inventory

Psychiatric Times

Knoll IV, MD November 19th 2024 4 Ways to Cope With Bipolar Uncertainty James Phelps, MD September 19th 2024 Borderline Personality Disorder and Complex Posttraumatic Stress Disorder: Myths in Diagnosis Mark L.

article thumbnail

sNDA Submitted: Lumateperone for the Prevention of Relapse in Schizophrenia

Psychiatric Times

An sNDA for Caplyta as an adjunctive treatment for adults with major depressive disorder (MDD) is also currently under FDA review, submitted back in December 2024. sNDA submitted: lumateperone as adjunctive therapy for major depressive disorder. December 3, 2024. points (effect size 0.61) in study 501 and 4.5

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PTSD Is Treatable, But There's No Holy Grail: Insights From Arash Javanbakht, MD

Psychiatric Times

August 9, 2024. September 11, 2024. Suicide risk in people with post-traumatic stress disorder: a cohort study of 3.1 but in what areas can we improve treatment outcomes and real-world functioning for patients with PTSD? but in what areas can we improve treatment outcomes and real-world functioning for patients with PTSD?

article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

September 2024. children and adolescents in 2022: diagnosis, severity, co-occurring disorders, and treatment. FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD. FDA Drug Safety Communication. June 30, 2025. CDC Growth Charts. Accessed July 1, 2025.

article thumbnail

The Psychiatric Pipeline in Review: Quarter 2, 2025

Psychiatric Times

Additionally, Vanda initiated a phase 3 clinical study for Bysanti as a once-daily adjunctive treatment for major depressive disorder in the fourth quarter of 2024. If approved, Bysanti could be available for sale in the US in 2026. Results are expected in 2026.

article thumbnail

TSND-201 Receives Breakthrough Therapy Designation From FDA for PTSD

Psychiatric Times

August 8, 2024. Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD. Press release. March 31, 2025. Officials, V eterans Urge Careful Consideration for MDMA-Assisted Psychotherapy. Psychiatric Times. Accessed July 10, 2025.

article thumbnail

99 Pubs and Zero Followers? Psychiatric Leadership in the Age of Influencers

Psychiatric Times

October 19, 2024. September 3, 2024. October 19, 2024. June 25, 2024. March 18, 2024. Gaslighting, narcissist, and more psychology terms you're misusing. March 15, 2023. Accessed April 10, 2025. When therapy goes wrong: the problem of underqualified psychotherapists. The Guardian. Accessed July 8, 2025.